Bacteria-mediated cancer therapy represents a novel and promising strategy for targeted drug delivery to solid tumors. Multiple studies have demonstrated that variousBifidobacteriumspecies can selectively colonize the hypoxic microenvironments characteristic of solid tumors. Leveraging this property,Bifidobacteriumhas been explored as a delivery vector for a range of anti-cancer approaches such as immunotherapy, nanoformulated chemotherapeutics, and gene therapy. Notably, anti-angiogenic genes such as endostatin and tumstatin have been successfully delivered to colorectal tumors usingBifidobacterium infantisandBifidobacterium longum, respectively. Additionally,Bifidobacterium bifidumhas been employed to transport doxorubicin and paclitaxel nanoparticles to breast and lung tumor sites. Furthermore, bothBifidobacterium longumandBifidobacterium bifidumhave been utilized to deliver nanoparticles that act as synergistic agents for high-intensity focused ultrasound (HIFU) therapy, significantly enhancing tumor ablation, particularly in triple-negative breast cancer (TNBC) models. While these pre-clinical findings are highly encouraging, further clinical research is essential. Specifically, studies are needed to investigate the colonization dynamics of differentBifidobacteriumspecies across various tumor types and to evaluate their potential in delivering diverse cancer therapies in human patients.
细菌介导的癌症疗法代表了一种新颖且有前景的实体瘤靶向给药策略。多项研究表明，多种双歧杆菌属菌种能够选择性定植于实体瘤特有的缺氧微环境。利用这一特性，双歧杆菌已被探索作为多种抗癌疗法的递送载体，包括免疫疗法、纳米化化疗药物及基因疗法。值得注意的是，血管生成抑制基因如内皮抑素和肿瘤抑素已分别通过婴儿双歧杆菌和长双歧杆菌成功递送至结直肠肿瘤。此外，双歧双歧杆菌已被用于将多柔比星和紫杉醇纳米颗粒递送至乳腺及肺部肿瘤部位。同时，长双歧杆菌与双歧双歧杆菌均被用于递送作为高强度聚焦超声（HIFU）治疗协同剂的纳米颗粒，显著增强肿瘤消融效果，在三阴性乳腺癌（TNBC）模型中尤为明显。尽管这些临床前研究结果极具前景，但仍需进一步的临床研究。具体而言，需要深入探究不同双歧杆菌菌种在各类肿瘤中的定植动力学，并评估其在人类患者中递送多种癌症疗法的潜力。
肿瘤(癌症)患者之家